Addition of Immune Checkpoint Inhibitor Showed Better Efficacy for Infiltrative Hepatocellular Carcinoma Receiving Hepatic Arterial Infusion Chemotherapy and Lenvatinib: A Multicenter Retrospective Study
The HAIC+Len+ICI group had a longer PFS and OS compared with the HAIC+Len group, demonstrating an acceptable safety profile. This triple combination strategy may be an alternative treatment for infiltrative HCC management.
Authors
- Ruixia Li (ORCID: https://orcid.org/0000-0002-0179-1807)
- Murong Wang
- Xiaohui Wang (ORCID: https://orcid.org/0000-0003-0544-2599)
- Hui Li (ORCID: https://orcid.org/0000-0003-4938-1783)
- Juncheng Wang (ORCID: https://orcid.org/0009-0007-2185-9526)
- Qunfang Zhou (ORCID: https://orcid.org/0000-0002-2533-3851)
- Wei Wang (ORCID: https://orcid.org/0000-0003-1568-222X)
Institutions
- Sun Yat-sen University (CN)
- Chinese PLA General Hospital (CN)
- The First Affiliated Hospital, Sun Yat-sen University (CN)
- Sun Yat-sen University Cancer Center (CN)
- Hunan Provincial People's Hospital (CN)
- Jinzhou Medical University (CN)
Publication Details
- Journal
- ImmunoTargets and Therapy
- Published
- 2024-08-01
- DOI
- https://doi.org/10.2147/itt.s470797
- Citations
- 6
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 2.22
Funders
- National Natural Science Foundation of China